Paul Blahunka

A Phase 1, Randomized Ascending Single-Dose Study of Antagonist Anti-Human CD40 ASKP1240 in Healthy Subjects

Ronald Goldwater, James J. Keirns, Paul Blahunka et al. · American Journal of Transplantation · 2013 · 68 citations · Full text

Healthy Subjects, Immunology, Pharmacotherapy +19

Pharmacodynamics and pharmacokinetics of esmolol, a short-acting β-blocking agent, in children

Bettina F. Cuneo, Vincent R. Zales, Paul Blahunka et al. · Pediatric Cardiology · 1994 · 34 citations

Short-acting β-Blocking Agent, Medicine, Mechanism Of Action +5

A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation

Flavio Vincenti, Göran Klintmalm, Harold C. Yang et al. · American Journal of Transplantation · 2019 · 33 citations · Full text

The MOBILE Study—A Phase IIa Enriched Enrollment Randomized Withdrawal Trial to Assess the Analgesic Efficacy and Safety of ASP8477, a Fatty Acid Amide Hydrolase Inhibitor, in Patients with Peripheral Neuropathic Pain

Daniel Bradford, Anjali Stirling, Étienne Ernault et al. · Pain Medicine · 2017 · 20 citations · Full text